Nimodipine

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Cell permeable: no

Primary TargetL-type Ca2⁺ channel blocker

Reversible: no

Product does not compete with ATP.

Target IC₅₀: 36 pM blocking TNF-α and LPS-induced iNOS activity in mouse astroglial cells

General description

An L-type Ca²⁺ channel blocker. Enhances memory in old or brain-damaged animals. Ameliorates experimental diabetic neuropathy in streptozotocin-induced diabetic rats.

An L-type Ca²⁺ channel blocker. Enhances memory in old or brain-damaged animals. Ameliorates experimental diabetic neuropathy in streptozotocin-induced diabetic rats. Also reported to block TNF-α and LPS-induced iNOS activity (IC₅₀ = 36 pM) in mouse astroglial cells.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Zhu, D., et al. 1999. Life. Sci.65, PL 221.Marchetti, C. and Usai, C. 1996. Neurosci. Lett. 207, 77.Kappelle, A.C., et al. 1994. Br. J. Pharmacol.111, 887.Weiss, J.H., et al. 1994. J. Neurochem. 62, 372.Kappelle, A.C., et al. 1993. Br. J. Pharmacol.108, 780.

Packaging

25 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Harmful & Carcinogenic / Teratogenic (E)